FUSED POLYPEPTIDE WITH ANTICANCER ACTIVITY Russian patent published in 2020 - IPC C07K14/47 C07K16/28 C07K16/32 C07K19/00 A61K39/395 A61P35/00 

FIELD: medicine; pharmaceuticals.

SUBSTANCE: invention relates to a fused polypeptide specific for both CD137 and HER2/neu, wherein the fused polypeptide can be used to guide formation of clusters and activation of CD137 with respect to HER2/neu-positive tumor cells. Present disclosure also relates to methods of producing a fused polypeptide described herein, as well as compositions containing such a fused polypeptide. Present disclosure further relates to nucleic acid molecules encoding such a fused polypeptide, and to methods of producing such a fused polypeptide and nucleic acid molecules. Present invention also discloses methods of using such a fused polypeptide in therapy and/or diagnostics, as well as compositions containing one or more such fused polypeptides.

EFFECT: such fused polypeptide can be used in many pharmaceutical routes of use, for example as anticancer agents and/or immunomodulators for treating or preventing human diseases, such as a number of tumors.

43 cl, 24 dwg, 9 tbl, 20 ex